NGS-based RNA-sequencing Market Size, Share & Trends Analysis Report By Product & Service (Consumables, Instruments, Services), By Workflow (Pre-sequencing, Sequencing, Data Analysis), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global NGS-based RNA-sequencing market was valued at USD 3.92 billion in 2024 and is projected to grow at a CAGR of 17.3% from 2025 to 2030. The market's growth is fueled by the increasing adoption of precision medicine, rising demand for transcriptome profiling, and advancements in high-throughput sequencing technologies. Additional drivers include expanding applications in biomarker discovery, drug development, and disease diagnostics. The decreasing cost of sequencing and growing investments in genomic research further accelerate the market’s expansion across clinical and research domains.

The COVID-19 pandemic positively impacted the NGS-based RNA-sequencing market by accelerating demand for genomic surveillance and virus tracking. NGS technologies, including RNA-seq, were critical in identifying viral mutations, supporting vaccine development, and enhancing diagnostic accuracy. The heightened global focus on infectious disease research increased sequencing infrastructure and innovation investments. This application surge expanded the market’s footprint during the pandemic. It paved the way for broader adoption of RNA-seq in clinical, pharmaceutical, and research settings in the post-pandemic landscape.

In addition, the rising demand for precision and personalized medicine is significantly driving the adoption of NGS-based RNA-sequencing technologies. These solutions enable deeper insights into gene expression and disease mechanisms, allowing for more targeted therapies and improved patient outcomes. As healthcare systems shift towards individualized treatment approaches, RNA-seq is essential for clinical decision-making and tailored therapeutic strategies.

Moreover, growing applications in biomarker discovery and drug development fuel market growth. NGS-based RNA-sequencing enables high-resolution gene expression analysis, facilitating the identification of novel biomarkers and therapeutic targets. This accelerates the drug discovery process, enhances clinical trial efficiency, and supports the development of more effective, targeted treatments, making RNA-seq a critical component in modern pharmaceutical and biotech research pipelines.

Accelerating Disease Insights Through Transcriptome Analysis

The increasing adoption of transcriptome analysis in disease research transforms how scientists understand the molecular basis of various conditions. Researchers can comprehensively view gene expression patterns, splice variants, and non-coding RNAs across different biological states by leveraging NGS-based RNA-sequencing. This high-resolution insight enables identification of disease-specific transcripts and regulatory mechanisms often missed by traditional gene expression methods. Recent advancements in transcriptome analysis have been delivering significant breakthroughs across various therapeutic areas. For instance, in June 2024, researchers at the University of Kentucky employed long-read RNA-sequencing to investigate the human frontal cortex in Alzheimer’s patients. Their findings revealed unique RNA isoforms associated with the disease, highlighting new avenues for early diagnostics and targeted intervention in neurodegenerative disorders.

In complex diseases such as cancer, neurological disorders, and autoimmune conditions, transcriptome analysis is pivotal in uncovering dysregulated pathways and potential biomarkers. It allows for the characterization of tumor heterogeneity, the discovery of fusion genes, and the monitoring of disease progression at the transcript level. These capabilities enhance diagnostic precision and support the development of targeted therapies that address the underlying molecular drivers of disease. For instance, in April 2025, an oncology multi-omics study focusing on esophageal adenocarcinoma identified the gene CTSB as a potential protective factor. Using transcriptome-wide association studies (TWAS) and single-cell RNA-sequencing, the study demonstrated that CTSB expression in macrophages may reduce cancer risk, opening possibilities for novel therapeutic targets in precision oncology.

Furthermore, integrating transcriptomics with other omics technologies-such as genomics, proteomics, and metabolomics-creates a multidimensional approach to disease research. This system’s biology perspective helps build comprehensive models of disease mechanisms, enabling predictive insights and facilitating personalized treatment strategies. As research institutions and biopharma companies continue to invest in transcriptome-driven studies, NGS-based RNA-sequencing is emerging as an indispensable tool in translational and clinical research settings. Additionally, per the article published in February 2024, transcriptomic approaches have led to identifying susceptibility genes in Crohn’s disease, offering insights into disease pathogenesis. These discoveries are paving the way for tailored treatment strategies based on individual gene expression profiles, reinforcing the value of RNA-sequencing as a cornerstone in the development of personalized medicine.

Technological Landscape of NGS Platforms in RNA-sequencing

The next-generation sequencing (NGS) market continues to evolve, with a diverse set of platforms offering specialized capabilities for RNA-sequencing. Each technology differs in read length, sequencing chemistry, amplification methods, and error rates-factors significantly influencing platform selection based on research or clinical objectives.

HiSeq Illumina remains a dominant platform due to its optimal balance of high accuracy (0.2% error rate), moderate read lengths (50-250 bp), and robust chemistry using reversible terminators and solid-phase PCR. This makes it suitable for various applications, including transcriptome profiling and differential gene expression analysis.

Table 1 Comparison of NGS platforms used in RNA-sequencing

Other platforms cater to specific sequencing needs. Ion Torrent, for instance, employs proton detection with emulsion PCR and provides mid-range read lengths (100-400 bp), offering flexibility with a manageable error rate of 1%. Meanwhile, PacBio and Oxford Nanopore Technologies are leading long-read sequencing solutions. PacBio delivers up to 14 kb reads with real-time sequencing, though with a higher error rate (15%). Nanopore sequencing, with read lengths around 10 kb and error rates ranging from 10-40%, offers unique advantages in real-time and direct RNA-sequencing without requiring amplification.

In summary, selecting an RNA-sequencing platform depends on project requirements such as accuracy, depth, speed, and cost. As advancements continue to reduce error rates and increase throughput, the market is poised for sustained innovation and growth across academic, pharmaceutical, and clinical domains.

Market Concentration & Characteristics

The NGS-based RNA-sequencing industry is set for exponential growth, driven by rising demand for precision medicine, advancements in sequencing technologies, and expanding applications in diagnostics and drug development. Increasing research in transcriptomics and biomarker discovery and declining sequencing costs further accelerate market adoption across clinical and pharmaceutical sectors.

The NGS-based RNA-sequencing industry is growing steadily, with moderate collaboration among industry players. Key drivers include the rising need for personalized medicine, advancements in high-throughput sequencing, and increasing use in disease research and drug discovery. Continued investments in genomics and bioinformatics are also enhancing data interpretation, supporting broader adoption across clinical and research applications.

Regulations play a critical role in shaping the NGS-based RNA-sequencing industry. They ensure data accuracy, patient safety, and clinical compliance, with stringent guidelines for diagnostic use, data privacy, and sequencing platform validation directly influencing product development and commercialization. While demanding, these regulatory frameworks enhance market credibility and drive innovation that is aligned with global healthcare standards.

The NGS-based RNA-sequencing industry has seen significant growth in product and service expansion, driven by increasing demand for high-throughput transcriptomic analysis, personalized medicine, and advanced diagnostic solutions. Continuous innovation, along with increasing investments in genomics research, allows for the creation of more accurate, scalable, and user-friendly sequencing platforms and support services, further accelerating market adoption across clinical and research domains.

The NGS-based RNA-sequencing industry is expanding strongly regionally, driven by rising healthcare investments, growing genomics research initiatives, and increased adoption of precision medicine. Enhanced access to advanced sequencing technologies and government support for biotech infrastructure further accelerate regional market growth, especially in emerging economies focused on strengthening diagnostic and research capabilities.

Product & Service Insights

The consumables segment dominated the market with a revenue share of 58.12% in 2024. This is attributed to the recurring demand for reagents, kits, and other consumables required at every stage of the sequencing workflow. As research activities and clinical applications expand, the need for high-quality, reliable consumables has increased significantly. Additionally, advancements in sequencing chemistry and the introduction of specialized kits for targeted RNA analysis have further driven segment growth, reinforcing its critical role in the overall NGS ecosystem.

The services segment is expected to grow at the fastest CAGR of 18.9% from 2025 to 2030. This growth is driven by increasing outsourcing of sequencing and data analysis to specialized service providers, rising demand for customized solutions, and limited in-house expertise among end users. Additionally, the complexity of bioinformatics and the need for scalable, cost-effective solutions are further accelerating the adoption of professional NGS services across research and clinical settings.

Workflow Insights

In 2024, the sequencing segment dominated the industry share. This is attributed to the increasing adoption of high-throughput sequencing technologies, which provide rapid and comprehensive insights into gene expression and transcriptomic profiles. The growth is further fueled by advancements in sequencing platforms that offer improved accuracy, scalability, and cost-effectiveness. As research and clinical applications in oncology, neurology, and personalized medicine continue to expand, the demand for next-generation sequencing technologies has surged. Additionally, the ability to sequence a wide range of RNA molecules, including mRNA, non-coding RNAs, and splice variants, has solidified the sequencing segment’s dominant position in the market.

The data analysis segment is expected to grow at the fastest CAGR from 2025 to 2030, driven by the increasing complexity of NGS data and the growing demand for accurate bioinformatics solutions. Advancements in AI, machine learning, and cloud-based platforms are enhancing data interpretation, enabling more precise insights. The need for scalable, automated solutions in research and clinical applications further fuels the segment's growth.

Application Insights

In 2024, drug discovery and development dominated the NGS-based RNA-sequencing market with a revenue share of 61.54%. This is attributed to the growing reliance on RNA-seq technologies to identify biomarkers, characterize disease mechanisms, and accelerate the discovery of novel drug targets. RNA-sequencing enables more precise gene expression profiling, facilitating the development of targeted therapies, particularly in oncology, neurology, and immunology. As pharmaceutical companies increasingly focus on personalized medicine, the ability to integrate RNA-seq data into drug discovery pipelines has become critical. Additionally, RNA-seq’s role in optimizing clinical trial design and improving drug efficacy further drives its dominance in the drug development sector.

The clinical diagnostics segment in the industry is expected to grow at the fastest CAGR from 2025 to 2030, owing to the increasing adoption of NGS technologies for precision diagnostics and personalized treatment plans. The ability to detect genetic mutations, identify disease markers, and offer tailored therapeutic options drives demand. Additionally, the growing focus on early disease detection and non-invasive diagnostic methods further accelerates market growth in this segment.

End Use Insights

In 2024, pharmaceutical & biotechnology companies held the largest market share of 36.64%. This is attributed to the extensive use of NGS-based RNA-sequencing in drug discovery, biomarker identification, and therapeutic development. These companies leverage RNA-seq technologies to gain deeper insight into disease mechanisms, validate drug targets, and optimize clinical trial designs. As personalized medicine continues gaining traction, pharmaceutical and biotech firms increasingly adopt RNA-seq to develop tailored therapies. The ability to integrate RNA-seq data into research and development pipelines drives significant investments and further solidifies their market dominance.

Meanwhile, the hospitals & clinics segment is expected to grow the fastest in the coming years, owing to the increasing adoption of NGS technologies for diagnostic purposes, personalized treatment plans, and non-invasive procedures. The growing demand for precise, real-time genomic insights to improve patient outcomes drives rapid expansion in this sector.

Competitive Scenario Insights

The NGS-based RNA-sequencing market is moderately fragmented, featuring a mix of global technology providers and niche players. Key companies such as Illumina, Inc., Thermo Fisher Scientific Inc., and Merck KGaA lead with strong portfolios in sequencing platforms, reagents, and bioinformatics tools. These firms are driving innovation through investments in high-throughput systems, automation, and AI-driven data analysis to support expanding applications in drug discovery, diagnostics, and precision medicine.

Mid-sized and emerging companies such as Pacific Biosciences of California, Inc., Oxford Nanopore Technologies Ltd., and Revvity, Inc. are contributing to market competitiveness through proprietary sequencing technologies and flexible platforms tailored to specific research needs. These players often focus on areas such as long-read sequencing, portable devices, and rapid clinical testing, allowing them to serve differentiated segments and compete against established giants.

Strategic collaborations, acquisitions, and regional expansions are shaping the competitive landscape, as companies aim to enhance technological capabilities and broaden their market reach. Players like QIAGEN N.V., Agilent Technologies, Inc., BGI Group, and Roche Holding AG are investing in integrated solutions and expanding their footprints in emerging markets. Despite rapid growth, challenges such as high costs, regulatory complexities, and evolving customer needs continue to influence competitive positioning.

Regional Insights

North America led the NGS-based RNA-sequencing industry with a revenue share of 48.17% in 2024, owing to advanced healthcare infrastructure, strong research initiatives, and substantial investments in genomics. The region’s robust pharmaceutical and biotechnology sectors and a high demand for personalized medicine further propelled market growth. Additionally, the presence of key industry players and government support for genomic research and innovation in North America continues to drive the adoption of RNA-sequencing technologies across clinical and research applications.

U.S. NGS-based RNA-sequencing Market Trends

The U.S. NGS-based RNA-sequencing market is growing rapidly due to significant investments in genomic research, advancements in healthcare infrastructure, and increasing demand for personalized medicine. Additionally, strong collaboration between biotech firms and academic institutions is accelerating innovation and adoption of RNA-sequencing technologies.

Europe NGS-based RNA-sequencing Market Trends

Europe is a key NGS-based RNA-sequencing market, driven by robust research initiatives and increasing genomics funding. The region's strong healthcare systems and adoption of personalized medicine further fuel market growth. Additionally, collaborations between academic institutions, pharmaceutical companies, and government agencies are accelerating the development and integration of RNA-sequencing technologies. Europe's focus on precision medicine and early disease detection also expands the market.

The UK NGS-based RNA-sequencing market is expanding owing to strong government support for genomics research and the growing demand for personalized medicine. Advancements in healthcare infrastructure and increasing collaborations between academia and industry drive market growth.

NGS-based RNA-sequencing market in Germany is growing rapidly due to strong government funding, advanced healthcare infrastructure, and rising adoption of precision medicine. Strategic collaborations between research institutions and biotech firms further support this growth.

Asia Pacific NGS-based RNA-sequencing Market Trends

The Asia Pacific NGS-based RNA-sequencing market is expected to grow the fastest at 18.18% CAGR from 2025 to 2030. This is attributed to increasing investments in healthcare infrastructure, expanding genomic research initiatives, and rising awareness of precision medicine. Countries like China, India, and Japan are rapidly adopting NGS technologies, driven by government support and growing biotech industries. The surge in population-based studies and demand for advanced diagnostics further accelerates regional market growth.

China NGS-based RNA-sequencing market is anticipated to witness significant growth due to the heavy government investment in genomics and a rapidly expanding biotech sector. The rising focus on precision medicine and large-scale population genomics projects further accelerates adoption.

NGS-based RNA-sequencing market in Japan held a strong share in 2024, supported by advanced healthcare infrastructure and a strong focus on innovation. Continued investment in genomics and personalized medicine is driving sustained market momentum.

MEA NGS-based RNA Sequencing Market Trends

The MEA NGS-based RNA sequencing market has experienced significant growth in recent years, fueled by several key factors. Countries like the UAE and Saudi Arabia are investing in advanced sequencing technologies to support national healthcare strategies and improve disease diagnostics. South Africa is emerging as a regional hub for genetic and transcriptomic research, particularly in oncology and infectious diseases. However, limited funding and infrastructure challenges in some regions may slow the widespread adoption of RNA sequencing technologies.

Saudi Arabia NGS-based RNA sequencing market is expanding due to government-driven genomic initiatives, increasing investments in biotechnology, and a growing emphasis on precision medicine. Programs such as the Saudi Human Genome Project are driving demand for RNA sequencing technologies. The country’s Vision 2030 strategy, which focuses on healthcare innovation, is fostering research in genetic diseases and gene expression studies. Collaborations between research institutes and global biotech firms are further accelerating market adoption.

NGS-based RNA sequencing market in Kuwait is emerging, propelled by increasing investments in healthcare research, genetic disease studies, and precision medicine initiatives. Government-backed programs and partnerships with global biotech firms are advancing genomic research, particularly in transcriptomics. However, limited local sequencing infrastructure and reliance on international partnerships may impede faster market expansion.

Key NGS-based RNA-sequencing Company Insights

Key players operating in the NGS-based RNA-sequencing market are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling market growth.

Recent Developments

• In March 2025, DNAnexus, Inc. and Alida Biosciences entered a strategic collaboration aimed at advancing research in epitranscriptomics, focusing on the intricate RNA modifications that influence gene expression. The partnership is expected to accelerate scientific discovery and enhance RNA-based analysis and innovation capabilities.

• In April 2025, SeqOne Genomics acquired Life & Soft to enhance its multi-omics and transcriptomics analysis capabilities. This acquisition integrates Life & Soft's ISO-certified sequencing platform, strengthening SeqOne's position in the NGS-based diagnostics market. It will enable SeqOne to offer more comprehensive, scalable, and compliant solutions for genomic data analysis, supporting hospitals, labs, and biopharma clients.

NGS-based RNA-sequencing Market Report Scope

Global NGS-based RNA-sequencing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global NGS-based RNA-sequencing market report based on product & service, workflow, application, end use, and region.

• Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumables

    • Extraction & Purification Kits

    • Library Preparation Kits

    • Sequencing Reagents & Flow Cells

    • Others

  • Instruments

  • Service           

    • RNA-sequencing

    • Bioinformatics & Data Analysis

• Workflow Outlook (Revenue, USD Million, 2018 - 2030)

  • Pre-sequencing

  • Sequencing

  • Data Analysis

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Drug Discovery & Development

    • Oncology

    • Infectious Diseases

    • Others

  • Clinical Diagnostics

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Academic & Research Institutes

  • Pharmaceutical & Biotechnology Companies

  • Hospitals & Clinics

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait